Investor attention is fixed on a critical regulatory milestone for biopharmaceutical firm aTyr Pharma. The company is ...

Sudbury workers' advocate Janice Martell says about 15 of the 700 miners she has registered who were exposed to aluminum dust known as McIntyre Powder have been diagnosed with a relatively rare ...

CEO Sanjay Shukla outlined the company’s strategy to develop new therapies for inflammation and fibrosis based on tRNA synthetase biology during a presentation at the Leerink Partners Global ...

The pooled global incidence and prevalence of progressive pulmonary fibrosis appear higher in the US than in Europe and South Korea.

Background Pulmonary fibrosis (PF) caused by interstitial lung diseases (ILDs) affects up to 0.1% of the global population. There is growing global interest in PF, evident from a nearly threefold ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine ...

Microbial involvement in sarcoidosis pathogenesis is suggested by the observation that histological findings in sarcoid granulomas are like those of leprosy, tuberculosis and parasitic infection. Some ...

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research, published at the ATS 2025 International ...

Abstract: Sarcoidosis, a multifaceted inflammatory disorder, often involves the $\prime$ lungs, presenting challenges in diagnosis and management. Computed tomography (CT) imaging is pivotal in ...

Pulmonary sarcoidosis is the most common and clinically relevant manifestation of this multisystem granulomatous disease, yet imaging tools that accurately reflect inflammatory activity remain limited ...